Utility of ancillary studies in the diagnosis and risk assessment of Barrett's esophagus and dysplasia.
Barrett's esophagus (BE) is a major risk factor for the development of esophageal adenocarcinoma (EAC). BE patients undergo periodic endoscopic surveillance with biopsies to detect dysplasia and EAC, but this strategy is imperfect owing to sampling error and inconsistencies in the diagnosis and grad...
| Publicado en: | Modern Pathology Vol. 35; no. 8; pp. 1000 - 1013 |
|---|---|
| Autores principales: | , , |
| Formato: | research Journal Article |
| Publicado: |
Elsevier B.V.
Aug2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=158164193&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 158164193 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 08933952 UNB jtl: Modern Pathology issn: 08933952 maglogo: N pubinfo: dt: Aug2022 vid: 35 iid: 8 pid: 467 pub: Elsevier B.V. place: New York, New York artinfo: ui: 158164193 158164193 NLM35260826 158164193 10.1038/s41379-022-01056-0 NLM35260826 158164193 ppf: 1000 ppct: 13 formats: tig: atl: Utility of ancillary studies in the diagnosis and risk assessment of Barrett's esophagus and dysplasia. aug: au: Choi, Won-Tak Lauwers, Gregory Y. Montgomery, Elizabeth A. affil: University of California at San Francisco, Department of Pathology, 94143, San Francisco, CA, USA sug: subj: Precancerous Conditions Diagnosis Precancerous Conditions Pathology Esophageal Neoplasms Diagnosis Barrett Esophagus Pathology Esophageal Neoplasms Precancerous Conditions Barrett Esophagus Diagnosis Esophageal Neoplasms Pathology Barrett Esophagus In Situ Hybridization, Fluorescence Adenocarcinoma Hyperplasia Human Risk Assessment ab: Barrett's esophagus (BE) is a major risk factor for the development of esophageal adenocarcinoma (EAC). BE patients undergo periodic endoscopic surveillance with biopsies to detect dysplasia and EAC, but this strategy is imperfect owing to sampling error and inconsistencies in the diagnosis and grading of dysplasia, which may result in an inaccurate diagnosis or risk assessment for progression to EAC. The desire for more accurate diagnosis and better risk stratification has prompted the investigation and development of potential biomarkers that might assist pathologists and clinicians in the management of BE patients, allowing more aggressive endoscopic surveillance and treatment options to be targeted to high-risk individuals, while avoiding frequent surveillance or unnecessary interventions in those at lower risk. It is known that progression of BE to dysplasia and EAC is accompanied by a host of genetic alterations, and that exploration of these markers could be potentially useful to diagnose/grade dysplasia and/or to risk stratify BE patients. Several biomarkers have shown promise in identifying early neoplastic transformation and thus may be useful adjuncts to histologic evaluation. This review provides an overview of some of the currently available biomarkers and assays, including p53 immunostaining, Wide Area Transepithelial Sampling with Three-Dimensional Computer-Assisted Analysis (WATS3D), TissueCypher, mutational load analysis (BarreGen), fluorescence in situ hybridization, and DNA content abnormalities as detected by DNA flow cytometry. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|